{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:36:05Z","timestamp":1757313365237},"publisher-location":"Cham","reference-count":50,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030345204"},{"type":"electronic","value":"9783030345211"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-34521-1_21","type":"book-chapter","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T08:05:40Z","timestamp":1586419540000},"page":"523-538","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Roneparstat: Development, Preclinical and Clinical Studies"],"prefix":"10.1007","author":[{"given":"Alessandro","family":"Noseda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,10]]},"reference":[{"key":"21_CR1","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.biocel.2006.06.004","volume":"38","author":"N Ilan","year":"2006","unstructured":"Ilan, N., Elkin, M., & Vlodavsky, I. (2006). Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Intl J Biochem & Cell Biol, 38, 2018\u20132039.","journal-title":"Intl J Biochem & Cell Biol"},{"key":"21_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bjp.0707182","volume":"151","author":"EA McKenzie","year":"2007","unstructured":"McKenzie, E. A. (2007). Heparanase: A target for drug discovery in cancer and inflammation. British Journal of Pharmacology, 151, 1\u201314.","journal-title":"British Journal of Pharmacology"},{"key":"21_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2174\/1568009614666140224155124","volume":"14","author":"V Masola","year":"2014","unstructured":"Masola, V., Secchi, M. F., Gambaro, G., & Onisto, M. (2014). Heparanase as a target in cancer therapy. Current Cancer Drug Targets, 14, 286\u2013293.","journal-title":"Current Cancer Drug Targets"},{"key":"21_CR4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4155\/fmc-2016-0012","volume":"8","author":"S Rivara","year":"2016","unstructured":"Rivara, S., Milazzo, F. M., & Giannini, G. (2016). Heparanase: A rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Medicinal Chemistry, 8, 647\u2013680.","journal-title":"Future Medicinal Chemistry"},{"key":"21_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.drup.2016.10.001","volume":"29","author":"I Vlodavsky","year":"2016","unstructured":"Vlodavsky, I., Singh, P., Boyango, I., Gutter-Kapon, L., Elkin, M., Sanderson, R. D., et al. (2016). Heparanase: From basic research to therapeutic applications in cancer and inflammation. Drug Res Updates., 29, 54\u201375.","journal-title":"Drug Res Updates."},{"issue":"Suppl 2","key":"21_CR6","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1016\/S0049-3848(14)50015-1","volume":"133","author":"Y Nadir","year":"2014","unstructured":"Nadir, Y., & Brenner, B. (2014). Heparanase multiple effects in cancer. Thrombosis Research, 133(Suppl 2), S90\u2013S94.","journal-title":"Thrombosis Research"},{"key":"21_CR7","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1158\/0008-5472.CAN-10-3402","volume":"71","author":"A Meirovitz","year":"2011","unstructured":"Meirovitz, A., Hermano, E., Lerner, I., Zcharia, E., Pisano, C., Peretz, T., et al. (2011). Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Research, 71, 2772\u20132780.","journal-title":"Cancer Research"},{"key":"21_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.matbio.2016.03.006","volume":"55","author":"VC Ramani","year":"2016","unstructured":"Ramani, V. C., Vlodavsky, I., Ng, M., Zhang, Y., Barbieri, P., Noseda, A., et al. (2016). Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix Biology, 55, 22\u201334.","journal-title":"Matrix Biology"},{"key":"21_CR9","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.18632\/oncotarget.6408","volume":"7","author":"VC Ramani","year":"2016","unstructured":"Ramani, V. C., Zhan, F., He, J., Barbieri, P., Noseda, A., Tricot, G., et al. (2016). Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget, 7, 1598\u20131607.","journal-title":"Oncotarget"},{"key":"21_CR10","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1158\/0008-5472.CAN-15-0037","volume":"75","author":"A Shteingauz","year":"2015","unstructured":"Shteingauz, A., Boyango, I., Naroditsky, I., Hammond, E., Gruber, M., Doweck, I., et al. (2015). Heparanase enhances tumor growth and chemoresistance by promoting autophagy. Cancer Research, 75, 3946\u20133957.","journal-title":"Cancer Research"},{"key":"21_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/febs.13932","volume":"284","author":"RD Sanderson","year":"2017","unstructured":"Sanderson, R. D., Elkin, M., Rapraeger, A. C., Ilan, N., & Vlodavsky, I. (2017). Heparanase regulation of cancer, autophagy and inflammation: New mechanisms and targets for therapy. The FEBS Journal, 284, 42\u201355.","journal-title":"The FEBS Journal"},{"key":"21_CR12","first-page":"137","volume":"7","author":"Q Lv","year":"2016","unstructured":"Lv, Q., Zeng, J., & He, L. (2016). The advancements of heparanase in fibrosis. Int J Mol Epidemiol Genet., 7, 137\u2013140.","journal-title":"Int J Mol Epidemiol Genet."},{"key":"21_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160074","volume":"11","author":"V Masola","year":"2016","unstructured":"Masola, V., Zaza, G., Gambaro, G., Onisto, M., Bellin, G., Vischini, G., et al. (2016). Heparanase: A potential new factor involved in the renal epithelial mesenchymal transition (EMT) induced by ischemia\/reperfusion (I\/R) injury. PLoS One, 11, e0160074.","journal-title":"PLoS One"},{"key":"21_CR14","doi-asserted-by":"publisher","first-page":"12103","DOI":"10.1074\/jbc.M414217200","volume":"280","author":"A Naggi","year":"2005","unstructured":"Naggi, A., Casu, B., Perez, M., Torri, G., Cassinelli, G., Penco, S., et al. (2005). Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. The Journal of Biological Chemistry, 280, 12103\u201312113.","journal-title":"The Journal of Biological Chemistry"},{"key":"21_CR15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.carbpol.2016.09.032","volume":"156","author":"A Alekseeva","year":"2017","unstructured":"Alekseeva, A., Mazzini, G., Giannini, G., & Naggi, A. (2017). Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat. Carbohydrate Polymers, 156, 470\u2013480.","journal-title":"Carbohydrate Polymers"},{"key":"21_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/glycob\/cww003","volume":"26","author":"D Pala","year":"2016","unstructured":"Pala, D., Rivara, S., Mor, M., Milazzo, F. M., Roscilli, G., Pavoni, E., et al. (2016). Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. Glycobiology, 26, 640\u2013654.","journal-title":"Glycobiology"},{"key":"21_CR17","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/1078-0432.CCR-10-2476","volume":"17","author":"JP Ritchie","year":"2011","unstructured":"Ritchie, J. P., Ramani, V. C., Ren, Y., Naggi, A., Torri, G., Casu, B., et al. (2011). SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase\/syndecan-1 axis. Clinical Cancer Research, 17, 1382\u20131393.","journal-title":"Clinical Cancer Research"},{"key":"21_CR18","doi-asserted-by":"crossref","first-page":"11299","DOI":"10.18632\/oncotarget.7170","volume":"7","author":"J Li","year":"2016","unstructured":"Li, J., Pan, Q., Rowan, P. D., Trotter, T. N., Peker, D., Regal, K. M., et al. (2016). Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells. Oncotarget, 7, 11299\u201311309.","journal-title":"Oncotarget"},{"key":"21_CR19","doi-asserted-by":"publisher","first-page":"30377","DOI":"10.1074\/jbc.M111.254789","volume":"286","author":"A Purushothaman","year":"2011","unstructured":"Purushothaman, A., Hurst, D. R., Pisano, C., Mizumoto, S., Sugahara, K., & Sanderson, R. D. (2011). Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. The Journal of Biological Chemistry, 286, 30377\u201330383.","journal-title":"The Journal of Biological Chemistry"},{"key":"21_CR20","doi-asserted-by":"publisher","first-page":"47848","DOI":"10.18632\/oncotarget.10292","volume":"7","author":"G Cassinelli","year":"2016","unstructured":"Cassinelli, G., Favini, E., Dal Bo, L., Tortoreto, M., De Maglie, M., Dagrada, G., et al. (2016). Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases. Oncotarget, 7, 47848\u201347863.","journal-title":"Oncotarget"},{"key":"21_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.canlet.2017.12.009","volume":"415","author":"G Cassinelli","year":"2018","unstructured":"Cassinelli, G., Dal Bo, L., Favini, E., Cominetti, D., Pozzi, S., Tortoreto, M., et al. (2018). Supersulfated low-molecular weight heparin synergizes with IGF1R\/IR inhibitor to suppress synovial sarcoma growth and metastases. Cancer Letters, 415, 187\u2013197.","journal-title":"Cancer Letters"},{"key":"21_CR22","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.bcp.2013.02.023","volume":"85","author":"G Cassinelli","year":"2013","unstructured":"Cassinelli, G., Lanzi, C., Tortoreto, M., Cominetti, D., Petrangolini, G., Favini, E., et al. (2013). Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochemical Pharmacology, 85, 1424\u20131432.","journal-title":"Biochemical Pharmacology"},{"doi-asserted-by":"crossref","unstructured":"Lanzi, C., & Cassinelli, G. (2018). Heparan sulfate mimetics in cancer therapy: The challenge to define structural determinants and the relevance of targets for optimal activity. Molecules, 23.","key":"21_CR23","DOI":"10.3390\/molecules23112915"},{"key":"21_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2016.09.004","volume":"382","author":"G Cassinelli","year":"2016","unstructured":"Cassinelli, G., Zaffaroni, N., & Lanzi, C. (2016). The heparanase\/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas. Cancer Letters, 382, 245\u2013254.","journal-title":"Cancer Letters"},{"key":"21_CR25","volume-title":"PCT Int Appl WO2018188990","author":"GNA Giannini","year":"2018","unstructured":"Giannini, G. N. A., & Esposito, E. (2018). Preparation of biotin-conjugated N-acetyl glycol split heparin as heparanase inhibitors. In PCT Int Appl WO2018188990."},{"doi-asserted-by":"crossref","unstructured":"Couchman, J. R., Multhaupt, H., & Sanderson, R. D. (2016). Recent insights into cell surface heparan sulphate proteoglycans and cancer. F1000Res, 5.","key":"21_CR26","DOI":"10.12688\/f1000research.8543.1"},{"key":"21_CR27","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/j.1582-4934.2010.01236.x","volume":"15","author":"RV Iozzo","year":"2011","unstructured":"Iozzo, R. V., & Sanderson, R. D. (2011). Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. Journal of Cellular and Molecular Medicine, 15, 1013\u20131031.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"21_CR28","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1182\/blood-2006-08-043232","volume":"109","author":"K Mahtouk","year":"2007","unstructured":"Mahtouk, K., Hose, D., Raynaud, P., Hundemer, M., Jourdan, M., Jourdan, E., et al. (2007). Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood, 109, 4914\u20134923.","journal-title":"Blood"},{"key":"21_CR29","doi-asserted-by":"publisher","first-page":"10093","DOI":"10.1074\/jbc.C112.444562","volume":"288","author":"CA Thompson","year":"2013","unstructured":"Thompson, C. A., Purushothaman, A., Ramani, V. C., Vlodavsky, I., & Sanderson, R. D. (2013). Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. The Journal of Biological Chemistry, 288, 10093\u201310099.","journal-title":"The Journal of Biological Chemistry"},{"key":"21_CR30","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/ndt\/gfx101.SO011","volume":"32","author":"V Masola","year":"2017","unstructured":"Masola, V., Granata, S., Bellin, G., Gambaro, G., Onisto, M., Rugiu, C., et al. (2017). Specific heparanase inhibition reverses glucose-induced mesothelial-to-mesenchymal transition. Nephrology, Dialysis, Transplantation, 32, 1145\u20131154.","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"21_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14946-0","volume":"7","author":"MF Secchi","year":"2017","unstructured":"Secchi, M. F., Crescenzi, M., Masola, V., Russo, F. P., Floreani, A., & Onisto, M. (2017). Heparanase and macrophage interplay in the onset of liver fibrosis. Scientific Reports, 7, 14956.","journal-title":"Scientific Reports"},{"key":"21_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.neo.2014.11.007","volume":"17","author":"L Zhang","year":"2015","unstructured":"Zhang, L., Ngo, J. A., Wetzel, M. D., & Marchetti, D. (2015). Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia, 17, 101\u2013113.","journal-title":"Neoplasia"},{"key":"21_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039899","volume":"7","author":"B Wang","year":"2012","unstructured":"Wang, B., Tan, Y. X., Jia, J., Digre, A., Zhang, X., Vlodavsky, I., et al. (2012). Accelerated resolution of AA amyloid in heparanase knockout mice is associated with matrix metalloproteases. PLoS One, 7, e39899.","journal-title":"PLoS One"},{"key":"21_CR34","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2011-05-355115","volume":"118","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos, M. A., & Kastritis, E. (2011). Bortezomib for AL amyloidosis: Moving forward. Blood, 118, 827\u2013828.","journal-title":"Blood"},{"key":"21_CR35","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3324\/haematol.2013.095463","volume":"99","author":"G Palladini","year":"2014","unstructured":"Palladini, G., Milani, P., Foli, A., Obici, L., Lavatelli, F., Nuvolone, M., et al. (2014). Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: Long-term results of a risk-adapted approach. Haematologica, 99, 743\u2013750.","journal-title":"Haematologica"},{"key":"21_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/hon.2466","volume":"36","author":"A Rossini","year":"2018","unstructured":"Rossini, A., Zunino, F., Ruggiero, G., De Cesare, M., Cominetti, D., Tortoreto, M., et al. (2018). Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat. Hematological Oncology, 36, 360\u2013362.","journal-title":"Hematological Oncology"},{"key":"21_CR37","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/j.1582-4934.2010.01190.x","volume":"15","author":"I Shafat","year":"2011","unstructured":"Shafat, I., Ben-Arush, M. W., Issakov, J., Meller, I., Naroditsky, I., Tortoreto, M., et al. (2011). Pre-clinical and clinical significance of heparanase in Ewing\u2019s sarcoma. Journal of Cellular and Molecular Medicine, 15, 1857\u20131864.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"21_CR38","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1096\/fj.07-8450com","volume":"21","author":"N Hostettler","year":"2007","unstructured":"Hostettler, N., Naggi, A., Torri, G., Ishai-Michaeli, R., Casu, B., Vlodavsky, I., et al. (2007). P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. The FASEB Journal, 21, 3562\u20133572.","journal-title":"The FASEB Journal"},{"key":"21_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1877-1173(10)93013-5","volume":"93","author":"X Zhang","year":"2010","unstructured":"Zhang, X., & Li, J. P. (2010). Heparan sulfate proteoglycans in amyloidosis. Progress in Molecular Biology and Translational Science, 93, 309\u2013334.","journal-title":"Progress in Molecular Biology and Translational Science"},{"key":"21_CR40","doi-asserted-by":"publisher","first-page":"36185","DOI":"10.18632\/oncotarget.26324","volume":"9","author":"V Masola","year":"2018","unstructured":"Masola, V., Bellin, G., Vischini, G., Dall\u2019Olmo, L., Granata, S., Gambaro, G., et al. (2018). Inhibition of heparanase protects against chronic kidney dysfunction following ischemia\/reperfusion injury. Oncotarget, 9, 36185\u201336201.","journal-title":"Oncotarget"},{"key":"21_CR41","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1096\/fj.201700597R","volume":"32","author":"V Masola","year":"2018","unstructured":"Masola, V., Zaza, G., Bellin, G., Dall\u2019Olmo, L., Granata, S., Vischini, G., et al. (2018). Heparanase regulates the M1 polarization of renal macrophages and their crosstalk with renal epithelial tubular cells after ischemia\/reperfusion injury. The FASEB Journal, 32, 742\u2013756.","journal-title":"The FASEB Journal"},{"key":"21_CR42","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2337\/db11-1024","volume":"61","author":"N Gil","year":"2012","unstructured":"Gil, N., Goldberg, R., Neuman, T., Garsen, M., Zcharia, E., Rubinstein, A. M., et al. (2012). Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes, 61, 208\u2013216.","journal-title":"Diabetes"},{"key":"21_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00715-6","volume":"7","author":"I Khamaysi","year":"2017","unstructured":"Khamaysi, I., Singh, P., Nasser, S., Awad, H., Chowers, Y., Sabo, E., et al. (2017). The role of heparanase in the pathogenesis of acute pancreatitis: A potential therapeutic target. Scientific Reports, 7, 715.","journal-title":"Scientific Reports"},{"key":"21_CR44","first-page":"1676","volume":"185","author":"J Huegel","year":"2015","unstructured":"Huegel, J., Enomoto-Iwamoto, M., Sgariglia, F., Koyama, E., & Pacifici, M. (2015). Heparanase stimulates chondrogenesis and is up-regulated in human ectopic cartilage. a mechanism possibly involved in hereditary multiple exostoses. Am J Pathol., 185, 1676\u20131685.","journal-title":"a mechanism possibly involved in hereditary multiple exostoses. Am J Pathol."},{"key":"21_CR45","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.3324\/haematol.2017.182865","volume":"103","author":"M Galli","year":"2018","unstructured":"Galli, M., Chatterjee, M., Grasso, M., Specchia, G., Magen, H., Einsele, H., et al. (2018). Phase I study of the heparanase inhibitor roneparstat: An innovative approach for ultiple myeloma therapy. Haematologica, 103, e469\u2013ee72.","journal-title":"Haematologica"},{"key":"21_CR46","volume-title":"PCT Int Appl WO2018177863","author":"GSD Giannini","year":"2018","unstructured":"Giannini, G. S. D., & Semeraro, F. (2018). Preparation of disodium 2,2\u2032-{carbonyl-bis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate compounds as heparanase inhibitors for the treatment of cancer. In PCT Int Appl WO2018177863."},{"key":"21_CR47","volume-title":"PCT Int Appl WO2018177861","author":"GSD Giannini","year":"2018","unstructured":"Giannini, G. S. D., & Oliva, P. (2018). Preparation of symmetrical tris-aryl-amide peptide derivatives and their use as anti-heparanase. In PCT Int Appl WO2018177861."},{"key":"21_CR48","volume-title":"PCT Int Appl WO2018177860","author":"GBG Giannini","year":"2018","unstructured":"Giannini, G. B. G., & Di Santo, R. (2018). Preparation of 2-(4-(4-(bromo-methoxybenzamido)benzylamino)phenyl)benzazole derivatives and their use as anti-heparanase. In PCT Int Appl WO2018177860."},{"unstructured":"Giannini G BG, Di Santo R Preparation of symmetrical 2-aminophenyl-benzazolyl-5-acetate compounds and their use as anti-heparanase. PCT Int Appl WO2018177857 A1 20181004. 2018.","key":"21_CR49"},{"key":"21_CR50","volume-title":"Patent: PCT Int Appl WO2018177865","author":"GMM Giannini","year":"2018","unstructured":"Giannini, G. M. M., & Rivara, S. (2018). Heparanase inhibitory compounds for therapeutic use in the treatment of proliferative disorders. In Patent: PCT Int Appl WO2018177865."}],"container-title":["Advances in Experimental Medicine and Biology","Heparanase"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-34521-1_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:40:49Z","timestamp":1615164049000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-34521-1_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030345204","9783030345211"],"references-count":50,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-34521-1_21","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"10 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}